Mozart Effect Myth: There is no research showing that Mozart's music has any effect on epilepsy

Published Date: 08 Mar 2023

Over the past 50 years, there has been much speculation about the quality of Wolfgang Amadeus Mozart's music. The report indicates that listening to Mozart's sonata KV448 in epilepsy patients reduces symptoms is interesting...

Read Full News

Latest News

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs Marco Meglio

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

NeurologyLive® Friday 5 — December 12, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine Isabella Ciccone, MPH

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

Todays Updates

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Todays Updates

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Latest News

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

News All Time

PERC Analysis Highlights Factors Influencing Candidacy for Pediatric Drug-Resistant Epilepsy Surgery Isabella Ciccone, MPH

A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.

Inside the 2026 MDA Conference: Keynote Insights and Evolving Neuromuscular Care Marco Meglio, Sharon Hesterlee, PhD

Sharon Hesterlee, PhD, President and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.

Stiripentol Reduces Seizure Burden in Patients with Lennox-Gastaut Syndrome, Study Shows Louie Pasculli

A new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.

Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program Marco Meglio

The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment for Dravet syndrome.

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

This Week on NeurologyLive® — December 8, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

Epidiolex CBD Treatment Effective Across Range of Developmental Epileptic Encephalopathies Marco Meglio

Recent analysis reveals Epidiolex significantly reduces seizures in patients with various developmental epileptic encephalopathies, showcasing its broad effectiveness.

Open Label Extension Confirms Cenobamate's Efficacy in Asian Populations Louie Pasculli

New data highlights cenobamate's effectiveness in reducing focal seizures in Asian populations, showcasing significant improvements and potential long-term benefits for patients.

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome Marco Meglio

New AES 2025 data reinforce zorevunersen’s disease-modifying potential in Dravet syndrome, showing durable seizure reduction, functional improvements, and a consistent safety profile.

NeurologyLive® Brain Games: December 7, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

NeurologyLive® Friday 5 — December 5, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

Japanese Post Marketing Study Shows Long-Term Efficacy of Stiripentol in Dravet Syndrome Isabella Ciccone, MPH

Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy Marco Meglio

A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic Isabella Ciccone, MPH

Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

Recommended News For You

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

Coffee and tea linked to lower head and neck cancer risk

'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma

Recommended Articles For You

Carboplatin Treatment: What You Need to Know About Side Effects and Efficacy  

Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease 

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined 

The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Invest in generics as a lesson from the shortages of chemotherapy.

2.

Big Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic Cancer

3.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

4.

The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.

5.

Similar survival seen with simple versus radical hysterectomy for cervical cancer

1.

Unveiling the Complexity of Multiple Myeloma Staging

2.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

3.

Clinical Analysis of Prostate Cancer

4.

Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology

5.

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part V

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

3.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

4.

Navigating the Complexities of Ph Negative ALL - Part III

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot